Tuesday, August 30, 2011

Small Players Like Chapel Hill Based Cempra: Solution for HAI Dearth?

 Given the difficulties Big Pharma is having with HAI treatments, as detailed in our Free White Paper,in terms of earning consistent revenue before their effectiveness and patents wear out, it may well be the small innovator companies that develop solutions.  This article covers Cempra's recent successful capital round for related to its drug TAKSTA, an oral medication designed to treat severely infected MRSA patients who require an oral formulation.  IV-intolerant patients may be candidates for their product.